KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

West Pharmaceutical Services (WST) Invested Capital (2016 - 2026)

West Pharmaceutical Services has reported Invested Capital over the past 18 years, most recently at $3.2 billion for Q1 2026.

  • Quarterly Invested Capital rose 10.66% to $3.2 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.2 billion through Mar 2026, up 10.66% year-over-year, with the annual reading at $3.4 billion for FY2025, 17.12% up from the prior year.
  • Invested Capital was $3.2 billion for Q1 2026 at West Pharmaceutical Services, down from $3.4 billion in the prior quarter.
  • Over five years, Invested Capital peaked at $3.4 billion in Q4 2025 and troughed at $2.6 billion in Q1 2022.
  • The 5-year median for Invested Capital is $3.0 billion (2023), against an average of $3.0 billion.
  • Biggest five-year swings in Invested Capital: rose 23.76% in 2022 and later fell 6.57% in 2024.
  • Tracing WST's Invested Capital over 5 years: stood at $2.9 billion in 2022, then grew by 6.7% to $3.1 billion in 2023, then decreased by 6.57% to $2.9 billion in 2024, then increased by 17.12% to $3.4 billion in 2025, then decreased by 5.49% to $3.2 billion in 2026.
  • According to Business Quant data, Invested Capital over the past three periods came in at $3.2 billion, $3.4 billion, and $3.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.